Between 1989 and 1993 , 710 pre - and perimenopausal women with axillary node-positive breast cancer were randomly assigned to either cyclophosphamide 75 mg/m ( 2 ) orally days 1 through 14 , epirubicin 60 mg/m ( 2 ) intravenously days 1 and 8 , and fluorouracil 500 mg/m ( 2 ) intravenously days 1 and 8 ( CEF ) or CMF ( cyclophosphamide 100 mg/m ( 2 ) orally days 1 through 14 , methotrexate 40 mg/m ( 2 ) intravenously days 1 and 8 , and fluorouracil 600 mg/m ( 2 ) intravenously days 1 and 8 ) .
